BEHIND RIABNI™ The amgen experience YOU'VE COME to trust

Introducing Riabni™

The rituximab biosimilar from Amgen, a proven leader in oncology biologics1

RIABNI™ is FDA approved for all Rituxan® oncology indications1,2,*

  • Non-Hodgkin's lymphoma (NHL)
    • Follicular lymphoma (FL)
    • Previously untreated large B-cell lymphoma
    • Non-progressing (stable disease)
  • Previously untreated chronic lymphocytic leukemia (CLL)
  • FDA = Food and Drug Administration.
  • *RIABNI™ is also indicated for the treatment of Granulomatosis with Polyangiitis (GPA) (Wegener's granulomatosis) and Microscopic Polyangiitis (MPA) in adult patients.